Skip to content
Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004

Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004

  • Post published:June 16, 2021
  • Post category:Press Release
Read more about the article Bright Minds Biosciences Announces Application to List on Nasdaq

Bright Minds Biosciences Announces Application to List on Nasdaq

  • Post published:June 16, 2021
  • Post category:Press Release
Read more about the article Optimi Health Completes Pre-Clinical Trial Application Meeting

Optimi Health Completes Pre-Clinical Trial Application Meeting

  • Post published:June 15, 2021
  • Post category:Press Release
Read more about the article PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression

PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression

  • Post published:June 15, 2021
  • Post category:Press Release
Read more about the article Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound

Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound

  • Post published:June 15, 2021
  • Post category:Press Release
Read more about the article Psychedelic Research Bulletin: May 2021

Psychedelic Research Bulletin: May 2021

  • Post published:June 14, 2021
  • Post category:Psychedelics Research Review
Read more about the article Psychedelic Bulletin: MindMed CEO Steps Down; Atai Targets $2.3bn Valuation

Psychedelic Bulletin: MindMed CEO Steps Down; Atai Targets $2.3bn Valuation

  • Post published:June 11, 2021
  • Post category:Psychedelic Bulletin
Read more about the article Filament Announces First GMP Batch of Pharmaceutical Grade Natural Psilocybin

Filament Announces First GMP Batch of Pharmaceutical Grade Natural Psilocybin

  • Post published:June 11, 2021
  • Post category:Press Release
Read more about the article atai Life Sciences Announces Launch of Initial Public Offering

atai Life Sciences Announces Launch of Initial Public Offering

  • Post published:June 11, 2021
  • Post category:Press Release
Read more about the article Atai Targets $2.3bn Valuation in Nasdaq IPO

Atai Targets $2.3bn Valuation in Nasdaq IPO

  • Post published:June 11, 2021
  • Post category:News

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More